Two Dose Levels of Privigen in Pediatric CIDP

Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Clinical Trial

Official title: Randomized Study of Two Dose Levels of Privigen in Pediatric CIDP

Status Recruiting

Clinical Trial Summary

A randomized, open-label, prospective, multicenter study designed to investigate 2 dose levels in pediatric subjects 2 to ≤ 17 years of age with confirmed or possible CIDP, either previously exposed to IVIG treatment or unexposed to IVIG treatment

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
• Polyneuropathies
• Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

• NCT number: NCT03684018
• Study type: Interventional
• Source: CSL Behring
• Contact: Trial Registration Coordinator
• Phone: 610-878-4000
• Email: clinicaltrials@cslbehring.com
• Status: Recruiting
• Phase: Phase 4
• Start date: February 28, 2019
• Completion date: December 20, 2029